Oda Takashi, Tsutsumi Koichiro, Obata Taisuke, Ueta Eijiro, Kikuchi Tatsuya, Ako Soichiro, Fujii Yuki, Yamazaki Tatsuhiro, Uchida Daisuke, Matsumoto Kazuyuki, Horiguchi Shigeru, Kato Hironari, Okada Hiroyuki, Chijimatsu Ryota, Otsuka Motoyuki
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan.
Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.
Mol Ther Oncol. 2024 Feb 8;32(1):200765. doi: 10.1016/j.omton.2024.200765. eCollection 2024 Mar 21.
Gallbladder cancer incidence has been increasing globally, and it remains challenging to expect long prognosis with the current systemic chemotherapy. We identified a novel nucleic acid-mediated therapeutic target against gallbladder cancer by using innovative organoid-based gallbladder cancer models generated from ; mice. Using comprehensive microRNA expression analyses and a bioinformatics approach, we identified significant microRNA-34a-5p downregulation in both murine gallbladder cancer organoids and resected human gallbladder cancer specimens. In three different human gallbladder cancer cell lines, forced microRNA-34a-5p expression inhibited cell proliferation and induced cell-cycle arrest at the G1 phase by suppressing direct target () expression. Furthermore, comprehensive RNA sequencing revealed the significant enrichment of gene sets related to the cell-cycle regulators after microRNA-34a-5p expression in gallbladder cancer cells. In a murine xenograft model, locally injected microRNA-34a-5p mimics significantly inhibited gallbladder cancer progression and downregulated expression. These results provide a rationale for promising therapeutics against gallbladder cancer by microRNA-34a-5p injection, as well as a strategy to explore therapeutic targets against cancers using organoid-based models, especially for those lacking useful genetically engineered murine models, such as gallbladder cancer.
全球范围内胆囊癌的发病率一直在上升,而目前的全身化疗要实现长期预后仍具有挑战性。我们通过使用从小鼠生成的基于类器官的创新胆囊癌模型,确定了一种针对胆囊癌的新型核酸介导治疗靶点。通过全面的微小RNA表达分析和生物信息学方法,我们在小鼠胆囊癌类器官和切除的人类胆囊癌标本中均发现了显著的微小RNA-34a-5p下调。在三种不同的人类胆囊癌细胞系中,强制表达微小RNA-34a-5p可抑制细胞增殖,并通过抑制直接靶点()的表达诱导细胞周期在G1期停滞。此外,全面的RNA测序显示,在胆囊癌细胞中表达微小RNA-34a-5p后,与细胞周期调节因子相关的基因集显著富集。在小鼠异种移植模型中,局部注射微小RNA-34a-5p模拟物可显著抑制胆囊癌进展并下调表达。这些结果为通过注射微小RNA-34a-5p治疗胆囊癌提供了理论依据,也为利用基于类器官的模型探索癌症治疗靶点提供了策略,尤其是对于那些缺乏有用的基因工程小鼠模型的癌症,如胆囊癌。